Key result
ARBs are linked to similar cardiac death or MI risk as ACE inhibitors in preserved LVEF STEMI.
Why the study?
Does an angiotensin receptor blocker reduce cardiac death or myocardial infarction compared to ACE inhibitors or no renin angiotensin system blocker in patients with ST segment elevation myocardial infarction and preserved left ventricular systolic function?
Cohort (n=6,698)
Yes
Does an angiotensin receptor blocker reduce cardiac death or myocardial infarction compared to ACE inhibitors or no renin angiotensin system blocker in patients with ST segment elevation myocardial infarction and preserved left ventricular systolic function?
In patients with ST segment elevation myocardial infarction and preserved left ventricular ejection fraction undergoing primary PCI, angiotensin receptor blockers are associated with similar clinical outcomes as ACE inhibitors and better outcomes than no renin angiotensin system blockade.
Answers are grounded in this paper and cite their sources.
Supports similar outcomes with ARBs versus ACE inhibitors in STEMI with preserved LVEF; leaves open need for randomized confirmation.
OBJECTIVE: To investigate the association between treatment with an angiotensin receptor blocker and clinical outcomes in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function. DESIGN: A prospective cohort study using data from a nationwide large scale registry. SETTING: 53 hospitals involved in treatment of acute myocardial infarction in Korea. PARTICIPANTS: Between November 2005 and September 2010, we studied 6698 patients with ST segment elevation myocardial infarction who underwent primary percutaneous coronary intervention and had a left ventricular ejection fraction ≥ 40%. MAIN OUTCOME MEASURES: Cardiac death or myocardial infarction. Patients were divided into an angiotensin receptor blocker group (n=1185), an angiotensin converting enzyme (ACE) inhibitor group (n=4564), and a group who did not receive any renin angiotensin system blocker (n=949). Propensity score matching analysis was also performed. RESULTS: Cardiac death or myocardial infarction occurred in 21 patients (1.8%) in the angiotensin receptor blocker group, 77 patients (1.7%) in the ACE inhibitor group, and 33 patients (3.5%) in the no renin angiotensin system blocker group. After propensity score matching (1175 pairs), there was no significant difference in the rate of cardiac death or myocardial infarction between the angiotensin receptor blocker group and ACE inhibitor group (21 (1.8%) v 23 (2.0%), adjusted hazard ratio 0.65, 95% confidence interval 0.30 to 1.38; P=0.65). The angiotensin receptor blocker group had a lower rate of cardiac death or myocardial infarction than the no renin angiotensin system blocker group in matched populations (803 pairs) (14 (1.7%) v 25 (3.1%), 0.35, 0.14 to 0.90; P=0.03). CONCLUSION: Angiotensin receptor blocker showed beneficial effects comparable with ACE inhibitors in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function. Angiotensin receptor blockers could be used as an alternative to ACE inhibitors in such patients.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2014) conducted a cohort in ST segment elevation myocardial infarction with preserved left ventricular systolic function (n=6,698). Angiotensin receptor blocker vs. ACE inhibitor was evaluated on Cardiac death or myocardial infarction (HR 0.65, 95% CI 0.30 to 1.38, p=0.65). Angiotensin receptor blockers were associated with similar rates of cardiac death or myocardial infarction compared to ACE inhibitors in STEMI patients with preserved LVEF.
Synapse has enriched 10 related papers. Consider them for comparative context: